We are live on ! Find out more
EUCR

Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR

Delisted

EUCR was delisted on the 26th of April, 2023.

Back to rankings

21 hedge funds and large institutions have $41.8M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

322% more capital invested

Capital invested by funds: $9.91M → $41.8M (+$31.9M)

320% more funds holding

Funds holding: 5 → 21 (+16)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
21
Holders Change
+16
Holders Change %
+320%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.5M
2
6CM
683 Capital Management
New York
+$6.16M
3
SC
Shay Capital
New York
+$4.63M
4
CH
CVI Holdings
Delaware
+$3.65M
5
SFM
Sphera Funds Management
Israel
+$3.12M

Top Sellers

Rank Fund Capital Flow
1
GPCM
Granite Point Capital Management
Massachusetts
-$1.88M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$36.1K

EUCR Hedge Fund Activity: Q1 2021 in Review

21 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q1 2021, worth a combined $41.8M — up 322% from $9.91M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new EUCR positions and 0 closed out — a net gain of 16 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $9.5M. The largest seller was Granite Point Capital Management, cutting an estimated $1.88M.

  • 21 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q1 2021, up from 5 in Q4 2020.
  • Funds reported $41.8M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q1 2021, up 322% quarter-over-quarter.
  • 16 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q1 2021 and 0 closed out, a net change of +16 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q1 2021 was BlackRock, an estimated $9.5M added.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q1 2021 was Granite Point Capital Management, an estimated $1.88M sold.

Based on aggregated 13F filings for Q1 2021.